Both MCI and AD patients have increased levels of advanced oxidation protein products. APOE4 carriers MCI have reduced plasma SOD activity relative to non-APOE4 carriers. Plasma reducing capacity AD < MCI < HC. This evidence concerns the gene SOD1 and Alzheimer disease.